Keyphrases
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
100%
Acute Lymphoblastic Leukemia
39%
Acute Myeloid Leukemia
36%
Overall Survival
34%
Graft-versus-host Disease (GvHD)
24%
Minimal Residual Disease
21%
Confidence Interval
20%
Multiple Myeloma
20%
Hazard Ratio
19%
Non-relapse Mortality
19%
Progression-free Survival
17%
Fludarabine
17%
Complete Remission
16%
Busulfan
16%
Myelodysplastic Syndrome
15%
Hematopoietic Cell Transplantation
14%
Chimeric Antigen Receptor T-cell Therapy
14%
Transplantation
14%
Hematopoietic Stem Cell Transplantation
14%
Chimeric Antigen Receptor T Cells (CAR-T)
13%
Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
13%
Unrelated Donor
13%
Post-transplantation Cyclophosphamide (PTCy)
13%
High Risk
12%
Pretransplant
12%
Relapsed or Refractory
11%
Transplant Outcomes
11%
Melphalan
10%
Gemtuzumab Ozogamicin
10%
First Complete Remission
10%
B-cell Acute Lymphoblastic Leukemia (B-ALL)
10%
Multiple Myeloma Patients
9%
Stem Cell Transplantation
9%
Leukemia Patients
9%
Conditioning Regimen
9%
Chemotherapy
9%
Adult Patients
9%
Reduced-intensity Conditioning
8%
Myeloablative
8%
Tyrosine Kinase Inhibitor
8%
Multivariate Analysis
8%
Older Adults
7%
Haploidentical
7%
Older Patients
7%
Allogeneic Transplantation
7%
Complete Response
7%
CD19
6%
Donor Age
6%
Relapse Risk
6%
Hyper-CVAD
6%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
49%
Hematopoietic Cell
46%
Overall Survival
41%
Transplantation
39%
Cell Transplantation
39%
Acute Myeloid Leukemia
38%
Multiple Myeloma
26%
Minimal Residual Disease
22%
Progression Free Survival
22%
Diseases
22%
Allogeneic Stem Cell Transplantation
21%
Hematopoietic Stem Cell Transplantation
20%
Hazard Ratio
20%
Myelodysplastic Syndrome
19%
Allogeneic Hematopoietic Stem Cell Transplantation
17%
Stem Cell Transplant
15%
Chimeric Antigen Receptor T-Cell Immunotherapy
14%
Autologous Hematopoietic Stem Cell Transplantation
14%
T Cell
13%
Busulfan
12%
Autologous Stem Cell Transplantation
11%
Fludarabine
10%
Graft Versus Host Reaction
10%
Philadelphia 1 Chromosome
10%
Allograft
10%
Tyrosine-Kinase Inhibitor
9%
Chimeric Antigen Receptor
9%
Conditioning
9%
Chimeric Antigen Receptor T-Cell
9%
Melphalan
8%
Cell Therapy
8%
Malignant Neoplasm
8%
Multivariate Analysis
8%
Cyclophosphamide
8%
Stem Cell Therapy
8%
Acute B-Cell Lymphoblastic Leukemia
7%
Large-Cell Lymphoma
7%
Leukemia
7%
Inotuzumab Ozogamicin
7%
Reduced Intensity Conditioning
6%
Clinical Trial
6%
Comorbidity
6%
Cytokine Release Syndrome
6%
B Cell
6%
Adolescence
6%
Acute Lymphocytic Leukemia
6%
Cumulative Incidence
5%
Lenalidomide
5%
Acute Graft Versus Host Disease
5%
Chronic Myelogenous Leukemia
5%
Immunology and Microbiology
Hematopoietic Cell
44%
Cell Transplantation
41%
Overall Survival
36%
Myeloid
28%
Conditioning
25%
Multiple Myeloma
25%
Allogeneic Hematopoietic Stem Cell Transplantation
21%
Progression Free Survival
20%
Hematopoietic Stem Cell Transplantation
18%
Cyclophosphamide
18%
Graft-Versus-Host Disease
17%
T Cell
17%
Allogeneic Stem Cell Transplantation
16%
B Cell
13%
Acute Graft Versus Host Disease
11%
Allograft
11%
Autologous Hematopoietic Stem Cell Transplantation
10%
Chimeric Antigen Receptor
9%
CD19
9%
Autologous Stem Cell Transplantation
8%
Engraftment
8%
Stem Cell Transplant
8%
Chimeric Antigen Receptor T-Cell Therapy
8%
Drug Megadose
7%
Philadelphia 1 Chromosome
7%
Tyrosine
5%
Chronic Graft Versus Host Disease
5%
Lenalidomide
5%
Chimeric Antigen Receptor T-Cell
5%
Stem Cell
5%
Cord Blood Stem Cell Transplantation
5%
Inotuzumab Ozogamicin
5%
